Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Post by dt_coreon Aug 02, 2011 4:09pm

207 Views

Post# 18896236

Trimble 2Q11 (HEM Data Point)

Looks like trimble reported VERY strong results in their Field Solutions (agriculture) division. This is a very strong data point for HEM, hopefully suggesting a strong quarter is indeed coming.

Trimble Field Solutions 2Q11

Second quarter 2011 Field Solutions revenue was $104.0 million, up 30 percent as compared to the second quarter of 2010 due primarily to very strong sales of agricultural products.

Second quarter 2010 Field Solutions operating income was $42.5 million, or 40.9 percent of revenue, as compared to $29.0 million, or 36.2 percent of revenue, in the second quarter of 2010. Non-GAAP operating income was $43.1, or 41.4 percent of revenue, as compared to $29.5 million, or 36.7 percent of revenue, in the second quarter of 2010. The increase in non-GAAP operating margin was due to higher revenue and product mix.